These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19435726)

  • 1. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?
    Zheng WJ; Zhang X; Wang Q; Xu D; Zeng XF; Zhang FC
    Ann Rheum Dis; 2009 Jun; 68(6):1077-8. PubMed ID: 19435726
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
    Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).
    Pinto LF; Candia L; Garcia P; Marín JI; Pachón I; Espinoza LR; Marquez J
    Respiration; 2009; 78(1):106-9. PubMed ID: 18799870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy response.
    Dunkley L; Green M; Gough A
    Rheumatology (Oxford); 2007 Oct; 46(10):1628-9. PubMed ID: 17766999
    [No Abstract]   [Full Text] [Related]  

  • 5. [Severe corticoid-refractory autoimmune thrombocytopenia associated with mixed connective tissue disease (Sharp's syndrome). Treatment with rituximab].
    Rudolph SE; Kouba M; Hrdlicka P
    Dtsch Med Wochenschr; 2009 Sep; 134(36):1734-8. PubMed ID: 19718594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy.
    Haroon M; O'Gradaigh D; Foley-Nolan D
    Rheumatology (Oxford); 2007 Apr; 46(4):718-9. PubMed ID: 17289791
    [No Abstract]   [Full Text] [Related]  

  • 7. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis: granulomatous disease more resistant than vasculitis disease?
    Wong CF
    J Clin Rheumatol; 2008 Apr; 14(2):61-4. PubMed ID: 18391671
    [No Abstract]   [Full Text] [Related]  

  • 10. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B-cell-directed therapy in patients with connective tissue diseases].
    Jacobi AM; Dörner T
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1755-7. PubMed ID: 22933200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-dose rituximab regimen in 7 patients with immune thrombocytopenia secondary to connective tissue disease].
    Wang HM; Yang YH; Xuan M
    Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):763-4. PubMed ID: 23336236
    [No Abstract]   [Full Text] [Related]  

  • 13. Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients.
    Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):235-6. PubMed ID: 20351494
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder.
    Gupta D; Roppelt H; Bowers B; Kunz D; Natarajan M; Gruber B
    J Clin Rheumatol; 2008 Apr; 14(2):94-6. PubMed ID: 18391679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rituximab: a new therapeutic arm in refractory rheumatoid arthritis: about one case].
    Abdelmoula LC; Testouri N; Ben Hadj Yahia C; Tekaya R; Ben M'barek R; Chaabouni L; Zouari R
    Tunis Med; 2008 Sep; 86(9):841-2. PubMed ID: 19472790
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of rituximab in refractory cold agglutinin disease.
    Panwar U; Mathews C; Cullis JO
    Int J Lab Hematol; 2008 Aug; 30(4):331-3. PubMed ID: 18665831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue disease following hepatitis B vaccination.
    Bruzzese V; Zullo A; Hassan C
    J Clin Rheumatol; 2013 Aug; 19(5):280-1. PubMed ID: 23872550
    [No Abstract]   [Full Text] [Related]  

  • 18. Interstitial lung disease: a rheumatologist's perspective.
    Fischer A
    J Clin Rheumatol; 2009 Mar; 15(2):95-9. PubMed ID: 19265357
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature.
    Dhand S; Bahrain H
    Cancer Invest; 2008 Nov; 26(9):913-5. PubMed ID: 19034773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.